Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × INDUSTRY × Solid Neoplasms × Clear all

Phase

Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 1303 Carcinoma, Non-Small-Cell Lung 631 Breast Neoplasms 491 Neoplasm Metastasis 446 Colorectal Neoplasms 369 Melanoma 338 Leukemia, Myeloid, Acute 316 Multiple Myeloma 312 Lymphoma 295 Ovarian Neoplasms 294 Recurrence 284 Advanced Solid Tumors 270 Lymphoma, Non-Hodgkin 264 Prostatic Neoplasms 245 Pancreatic Neoplasms 236 Advanced Solid Tumor 203 Carcinoma, Renal Cell 195 Stomach Neoplasms 189 Squamous Cell Carcinoma of Head and Neck 176 Solid Tumor 176 Lung Neoplasms 175 Leukemia, Lymphocytic, Chronic, B-Cell 167 Triple Negative Breast Neoplasms 151 Solid Tumors 151 Carcinoma, Hepatocellular 139 Lymphoma, Large B-Cell, Diffuse 131 Hematologic Neoplasms 131 Head and Neck Neoplasms 128 Lymphoma, Follicular 125 Myelodysplastic Syndromes 121

Interventions

pembrolizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03364049 2021-11-15

MK-7162-002

Merck Sharp & Dohme LLC

Phase 1 Completed

33 enrolled 19 charts

Solid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡